Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The subject has a functioning ileostomy that has been in place for ≥ 3 months.~* The subject is male or female between the ages of 18 and 80 years, inclusive.~* Other than a functioning ileostomy, the subject is free from clinically significant illnesses or disease.~Exclusion Criteria:~* Subjects who have active hepatic, small intestine, or biliary tract disease.~* Subjects who have active ulcerative colitis, Crohn's disease, other inflammatory bowel disease.~* Subjects with known malignancy requiring treatment \< 6 months prior to study screening.~* Subjects who have, in the opinion of the investigator, significant concurrent medical illness.~* Subjects who are currently taking concomitant medications which may interfere with study evaluation.~* Subjects who have received an investigational drug within 30 days or within a time period consistent with a washout period of 5 half-lives, whichever is longer, of the first dose of ceftriaxone.~* Subjects with a known history of allergy to any cephalosporin, penicillin or any β-lactam antibiotic.~* Subjects who have known active malabsorption syndromes(s) that, in the judgment of the investigator, could compromise the objectives of the study.~* Subjects who have used any oral, intramuscular, or IV anti-microbial medication during the last 3 week

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- 150 mg SYN-004 (Type: EXPERIMENTAL): There will be 2 in-house treatment periods: in Treatment Period 1, subjects will receive 2 oral doses of 150 mg SYN-004 (two 75 mg capsules) and 1g ceftriaxone, and in Treatment Period 2, subjects will receive 2 oral doses of 150mg SYN-004 (two 75 mg capsules) and 1g ceftriaxone in the presence of steady-state esomeprazole; Treatment Periods 1 and 2 will be separated by a 5- to 7-day run-in phase, during which subjects will self-administer 40 mg of esomeprazole once daily (QD) in the morning, at home.

Based on this trial design, predict the completion outcome and termination type (if applicable).